|
25/11/2024
|
07:00
|
Blenrep combinations accepted for US FDA review
|
RNS
|
|
22/11/2024
|
07:00
|
Japan approves first RSV vaccine for adults 50-59
|
RNS
|
|
19/11/2024
|
15:30
|
Director/PDMR Shareholding
|
RNS
|
|
19/11/2024
|
07:00
|
GLISTEN Trial of Linerixibat Meets Endpoint
|
RNS
|
|
14/11/2024
|
07:00
|
GSK announces overall survival results for Blenrep
|
RNS
|
|
13/11/2024
|
15:00
|
Block listing Interim Review
|
RNS
|
|
12/11/2024
|
15:30
|
Director/PDMR Shareholding
|
RNS
|
|
11/11/2024
|
15:01
|
GSK publishes provisional 2025 dividend dates
|
RNS
|
|
01/11/2024
|
15:00
|
Total Voting Rights
|
RNS
|
|
30/10/2024
|
14:29
|
Director/PDMR Shareholding
|
RNS
|
|
30/10/2024
|
07:00
|
3rd Quarter Results
|
RNS
|
|
24/10/2024
|
07:00
|
New positive Arexvy data in younger adults at risk
|
RNS
|
|
17/10/2024
|
15:30
|
Director/PDMR Shareholding
|
RNS
|
|
16/10/2024
|
16:09
|
Director/PDMR Shareholding
|
RNS
|
|
16/10/2024
|
07:00
|
FDA accepts new drug application for gepotidacin
|
RNS
|
|
14/10/2024
|
15:30
|
Director/PDMR Shareholding
|
RNS
|
|
14/10/2024
|
07:00
|
Positive results of ANCHOR trials of depemokimab
|
RNS
|
|
11/10/2024
|
15:33
|
Director/PDMR Shareholding
|
RNS
|
|
10/10/2024
|
15:30
|
Director/PDMR Shareholding
|
RNS
|
|
09/10/2024
|
17:48
|
Zantac (ranitidine) litigation settlements
|
RNS
|
|
08/10/2024
|
11:45
|
Positive efficacy data of Arexvy over 3 seasons
|
RNS
|
|
01/10/2024
|
15:00
|
Total Voting Rights
|
RNS
|
|
24/09/2024
|
15:30
|
Director/PDMR Shareholding
|
RNS
|
|
24/09/2024
|
07:00
|
Positive EU opinion for GSK liquid Menveo vaccine
|
RNS
|
|
18/09/2024
|
13:20
|
Statement: Zantac (ranitidine) litigation
|
RNS
|
|
17/09/2024
|
07:00
|
Japan Filing Acceptance: Blenrep Multiple Myeloma
|
RNS
|
|
13/09/2024
|
07:00
|
China Breakthrough Therapy Designation for Blenrep
|
RNS
|
|
12/09/2024
|
15:30
|
Director/PDMR Shareholding
|
RNS
|
|
12/09/2024
|
07:00
|
Positive mRNA flu vaccine Phase II headline data
|
RNS
|
|
11/09/2024
|
17:27
|
Statement: Zantac (ranitidine) litigation
|
RNS
|
|
11/09/2024
|
15:30
|
Change of Registered Office
|
RNS
|
|
11/09/2024
|
07:00
|
Update on phase I/II therapeutic HSV vaccine trial
|
RNS
|
|
09/09/2024
|
14:30
|
Depemokimab late-breaking data presented at ERS
|
RNS
|
|
06/09/2024
|
15:30
|
Director/PDMR Shareholding
|
RNS
|
|
06/09/2024
|
07:00
|
Positive Phase III results for Nucala in COPD
|
RNS
|
|
02/09/2024
|
15:00
|
Total Voting Rights
|
RNS
|
|
29/08/2024
|
07:00
|
EMA approval on Arexvy for 50-59 at risk
|
RNS
|
|
28/08/2024
|
07:10
|
SENKU Designation for Bepirovirsen in Japan
|
RNS
|
|
28/08/2024
|
07:05
|
Nucala approved in Japan for use in CRSwNP
|
RNS
|
|
28/08/2024
|
07:00
|
Statement: Zantac (ranitidine) litigation
|
RNS
|
|
21/08/2024
|
15:30
|
Director/PDMR Shareholding
|
RNS
|
|
20/08/2024
|
15:30
|
Director/PDMR Shareholding
|
RNS
|
|
20/08/2024
|
07:00
|
B7-H3 ADC US FDA Breakthrough Therapy Designation
|
RNS
|
|
16/08/2024
|
07:00
|
Statement: Zantac (ranitidine) litigation
|
RNS
|
|
12/08/2024
|
15:30
|
Director/PDMR Shareholding
|
RNS
|
|
06/08/2024
|
07:00
|
Statement: Zantac (ranitidine) litigation
|
RNS
|
|
02/08/2024
|
07:00
|
FDA Expands Jemperli Approval
|
RNS
|
|
01/08/2024
|
15:00
|
Total Voting Rights
|
RNS
|
|
31/07/2024
|
07:00
|
2nd Quarter Results
|
RNS
|
|
29/07/2024
|
08:18
|
Statement: Zantac (ranitidine) litigation
|
RNS
|